Drugging topoisomerases: Lessons and Challenges

ACS Chemical Biology

Volumn 8, Issue 1, 2013, Pages 82-95

  Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; BELOTECAN; CAMPTOTHECIN; COUMAMYCIN; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ELLIPTICINE; EPIRUBICIN; ETIRINOTECAN PEGOL; ETOPOSIDE; GEMIFLOXACIN; GIMATECAN; INDENOISOQUINOLINE; IRINOTECAN; LEVOFLOXACIN; LMP 400; LMP 776; MERBARONE; MITOXANTRONE; MOXIFLOXACIN; NALIDIXIC ACID; NK 102; NOVOBIOCIN; OXOLINIC ACID; RAZOXANE; TENIPOSIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOSAROXIN;

ACUTE LEUKEMIA; ANAPLASTIC THYROID CANCER; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CARDIOTOXICITY; CATALYSIS; COLON CANCER; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DNA STRUCTURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; ENDOCRINE TUMOR; ENZYME INHIBITION; ESOPHAGUS CANCER; EWING SARCOMA; GERM CELL TUMOR; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; KAPOSI SARCOMA; LUNG SMALL CELL CANCER; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SARCOMA; SOFT TISSUE SARCOMA; STOMACH CANCER; TESTIS TUMOR; THYROID CANCER; UTERINE CERVIX CANCER;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR STRUCTURE; TOPOISOMERASE INHIBITORS;

EID: 84872547120     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb300648v     Document Type: Review

References (155)

1. Nitiss, J. L. (2009) Targeting DNA topoisomerase II in cancer chemotherapy Nat. Rev. Cancer 9, 338-350
2. Nitiss, J. L. (2009) DNA topoisomerase II and its growing repertoire of biological functions Nat. Rev. Cancer 9, 327-337
3. Pommier, Y. (2009) DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition Chem. Rev. 109, 2894-2902
4. Pommier, Y. and Cushman, M. (2009) The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives Mol. Cancer Ther. 8, 1008-1014
5. Pommier, Y., Leo, E., Zhang, H., and Marchand, C. (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs Chem. Biol. 17, 421-433
6. Pommier, Y. and Marchand, C. (2012) Interfacial inhibitors: targeting macromolecular complexes Nat. Rev. Drug Discovery 11, 25-36
7. Deweese, J. E. and Osheroff, N. (2009) The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing Nucleic Acids Res. 37, 738-748
8. Schoeffler, A. J. and Berger, J. M. (2008) DNA topoisomerases: harnessing and constraining energy to govern chromosome topology Q. Rev. Biophys. 41, 41-101
9. Mitscher, L. A. (2005) Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents Chem. Rev. 105, 559-592 (Pubitemid 40351634)
10. Dalhoff, A. (2012) Global fluoroquinolone resistance epidemiology and implictions for clinical use Interdiscip. Perspect. Infect. Dis. 2012, 976273
11. Bailly, C. (2012) Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy Chem. Rev. 112, 3611-3640
12. Fortune, J. M. and Osheroff, N. (2000) Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice Prog. Nucleic Acid Res. Mol. Biol. 64, 221-253
13. Forterre, P., Gribaldo, S., Gadelle, D., and Serre, M. C. (2007) Origin and evolution of DNA topoisomerases Biochimie 89, 427-446 (Pubitemid 46656307)
14. Forterre, P. (2012) In DNA Topoisomerases and Cancer (Pommier, Y., Ed.) Springer, New York.
15. Viard, T. and de la Tour, C. B. (2007) Type IA topoisomerases: a simple puzzle? Biochimie 89, 456-467 (Pubitemid 46656306)
16. Gellert, M. (1981) DNA topoisomerases Annu. Rev. Biochem. 50, 879-910
17. Wang, J. C. (1996) DNA topoisomerases Annu. Rev. Biochem. 65, 635-692 (Pubitemid 26250622)
18. Champoux, J. J. (2001) DNA topoisomerases: structure, function, and mechanism Annu. Rev. Biochem. 70, 369-413 (Pubitemid 32662215)
19. Wang, J. C. (2009) Untangling the Double Helix, Cold Spring Harbor Press, Cold Spring Harbor, NY.
20. Redinbo, M. R., Stewart, L., Champoux, J. J., and Hol, W. G. (1999) Structural flexibility in human topoisomerase I revealed in multiple non-isomorphous crystal structures J. Mol. Biol. 292, 685-696 (Pubitemid 29457328)
21. Koster, D. A., Croquette, V., Dekker, C., Shuman, S., and Dekker, N. H. (2005) Friction and torque govern the relaxation of DNA supercoils by eukaryotic topoisomerase IB Nature 434, 671-674 (Pubitemid 40488562)
22. Koster, D. A., Palle, K., Bot, E. S., Bjornsti, M. A., and Dekker, N. H. (2007) Antitumour drugs impede DNA uncoiling by topoisomerase I Nature 448, 213-217 (Pubitemid 47067371)
23. Seol, Y., Zhang, H., Pommier, Y., and Neuman, K. C. (2012) A kinetic clutch governs religation by type IB topoisomerases and determines camptothecin sensitivity Proc. Natl. Acad. Sci. U.S.A. 109, 16125-16130
24. Schmidt, B. H., Osheroff, N., and Berger, J. M. (2012) Structure of a topoisomerase II-DNA-nucleotide complex reveals a new control mechanism for ATPase activity Nat. Struct. Mol. Biol. 19, 1147-1154
25. Schoeffler, A. J. and Berger, J. M. (2005) Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism Biochem. Soc. Trans. 33, 1465-1470 (Pubitemid 41779716)
26. Wu, L. and Hickson, I. D. (2003) The Bloom's syndrome helicase suppresses crossing over during homologous recombination Nature 426, 870-874 (Pubitemid 38056876)
27. Pommier, Y. and Cherfils, J. (2005) Interfacial protein inhibition: a nature's paradigm for drug discovery Trends Pharmacol. Sci. 28, 136-145
28. Pommier, Y. and Marchand, C. (2005) Interfacial inhibitors of protein-nucleic acid interactions Curr. Med. Chem. Anti-Cancer Agents 5, 421-429 (Pubitemid 40974814)
29. Capranico, G., Kohn, K. W., and Pommier, Y. (1990) Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin Nucleic Acids Res. 18, 6611-6619
30. Pommier, Y., Capranico, G., Orr, A., and Kohn, K. W. (1991) Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide Nucleic Acids Res. 19, 5973-5980 (Pubitemid 21913012)
31. Capranico, G. and Binaschi, M. (1998) DNA sequence selectivity of topoisomerases and topoisomerase poisons Biochim. Biophys. Acta 1400, 185-194 (Pubitemid 28475103)
32. Jaxel, C., Capranico, G., Kerrigan, D., Kohn, K. W., and Pommier, Y. (1991) Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin J. Biol. Chem. 266, 20418-20423 (Pubitemid 21908475)
33. Wall, M. E. and Wani, M. C. (1995) Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award lecture Cancer Res. 55, 753-760
34. Pommier, Y., Pourquier, P., Urasaki, Y., Wu, J., and Laco, G. (1999) Topoisomerase I inhibitors: selectivity and cellular resistance Drug Resist. Updates 2, 307-318 (Pubitemid 30070455)
35. Staker, B. L., Hjerrild, K., Feese, M. D., Behnke, C. A., Burgin, A. B., Jr., and Stewart, L. (2002) The mechanism of topoisomerase I poisoning by a camptothecin analog Proc. Natl. Acad. Sci. U.S.A. 99, 15387-15392 (Pubitemid 35403944)
36. Staker, B. L., Feese, M. D., Cushman, M., Pommier, Y., Zembower, D., Stewart, L., and Burgin, A. B. (2005) Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex J. Med. Chem. 48, 2336-2345 (Pubitemid 40516428)
37. Ioanoviciu, A., Antony, S., Pommier, Y., Staker, B. L., Stewart, L., and Cushman, M. (2005) Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis J. Med. Chem. 48, 4803-4814 (Pubitemid 41033123)
38. Marchand, C., Antony, S., Kohn, K. W., Cushman, M., Ioanoviciu, A., Staker, B. L., Burgin, A. B., Stewart, L., and Pommier, Y. (2006) A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of topoisomerase I-DNA covalent complexes Mol. Cancer Ther. 5, 287-295
39. Laponogov, I., Sohi, M. K., Veselkov, D. A., Pan, X. S., Sawhney, R., Thompson, A. W., McAuley, K. E., Fisher, L. M., and Sanderson, M. R. (2009) Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases Nat. Struct. Mol. Biol. 16, 667-669
40. Laponogov, I., Pan, X. S., Veselkov, D. A., McAuley, K. E., Fisher, L. M., and Sanderson, M. R. (2010) Structural basis of gate-DNA breakage and resealing by type II topoisomerases PLoS ONE 5, 8
41. Bax, B. D., Chan, P. F., Eggleston, D. S., Fosberry, A., Gentry, D. R., Gorrec, F., Giordano, I., Hann, M. M., Hennessy, A., Hibbs, M., Huang, J., Jones, E., Jones, J., Brown, K. K., Lewis, C. J., May, E. W., Saunders, M. R., Singh, O., Spitzfaden, C. E., Shen, C., Shillings, A., Theobald, A. J., Wohlkonig, A., Pearson, N. D., and Gwynn, M. N. (2010) Type IIA topoisomerase inhibition by a new class of antibacterial agents Nature 466, 935-940
42. Wu, C. C., Li, T. K., Farh, L., Lin, L. Y., Lin, T. S., Yu, Y. J., Yen, T. J., Chiang, C. W., and Chan, N. L. (2011) Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide Science 333, 459-462
43. Hsiang, Y. H., Hertzberg, R., Hecht, S., and Liu, L. F. (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I J. Biol. Chem. 260, 14873-14878 (Pubitemid 16211028)
44. Eng, W. K., Faucette, L., Johnson, R. K., and Sternglanz, R. (1988) Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin Mol. Pharmacol. 34, 755-760 (Pubitemid 19014396)
45. Nitiss, J. and Wang, J. C. (1988) DNA topoisomerase-targeting antitumor drugs can be studied in yeast Proc. Natl. Acad. Sci. U.S.A. 85, 7501-7505
46. Miao, Z. H., Player, A., Shankavaram, U., Wang, Y. H., Zimonjic, D. B., Lorenzi, P. L., Liao, Z. Y., Liu, H., Shimura, T., Zhang, H. L., Meng, L. H., Zhang, Y. W., Kawasaki, E. S., Popescu, N. C., Aladjem, M. I., Goldstein, D. J., Weinstein, J. N., and Pommier, Y. (2007) Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses Cancer Res. 67, 8752-8761 (Pubitemid 47437451)
47. Covey, J. M., Jaxel, C., Kohn, K. W., and Pommier, Y. (1989) Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I Cancer Res. 49, 5016-5022 (Pubitemid 19239335)
48. Subramanian, D., Kraut, E., Staubus, A., Young, D. C., and Muller, M. T. (1995) Analysis of topoisomerase I/DNA complexes in patients administered topotecan Cancer Res. 55, 2097-2103
49. Padget, K., Carr, R., Pearson, A. D., Tilby, M. J., and Austin, C. A. (2000) Camptothecin-stabilised topoisomerase I-DNA complexes in leukaemia cells visualised and quantified in situ by the TARDIS assay (trapped in agarose DNA immunostaining) Biochem. Pharmacol. 59, 629-638 (Pubitemid 30085444)
50. Dexheimer, T. S. and Pommier, Y. (2008) DNA cleavage assay for the identification of topoisomerase I inhibitors Nat. Protoc. 3, 1736-1750
51. Antony, S., Agama, K. K., Miao, Z. H., Takagi, K., Wright, M. H., Robles, A. I., Varticovski, L., Nagarajan, M., Morrell, A., Cushman, M., and Pommier, Y. (2007) Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance Cancer Res. 67, 10397-10405 (Pubitemid 350070815)
52. Rasheed, Z. A. and Rubin, E. H. (2003) Mechanisms of resistance to topoisomerase I-targeting drugs Oncogene 22, 7296-7304 (Pubitemid 37487161)
53. Beretta, G. L., Perego, P., and Zunino, F. (2006) Mechanisms of cellular resistance to camptothecins Curr. Med. Chem. 13, 3291-3305 (Pubitemid 44669776)
54. Burgess, D. J., Doles, J., Zender, L., Xue, W., Ma, B., McCombie, W. R., Hannon, G. J., Lowe, S. W., and Hemann, M. T. (2008) Topoisomerase levels determine chemotherapy response in vitro and in vivo Proc. Natl. Acad. Sci. U.S.A. 105, 9053-9058
55. O'Malley, F. P., Chia, S., Tu, D., Shepherd, L. E., Levine, M. N., Bramwell, V. H., Andrulis, I. L., and Pritchard, K. I. (2009) Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy J. Natl. Cancer Inst. 101, 644-650
56. Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., and Liu, L. F. (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II Science 226, 466-468 (Pubitemid 14012819)
57. Capranico, G., Riva, A., Tinelli, S., Dasdia, T., and Zunino, F. (1987) Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei Cancer Res. 47, 3752-3756 (Pubitemid 17105721)
58. Kohn, K. W. (1996) Beyond DNA cross-linking: history and prospects of DNA-targeted cancer treatment-fifteenth Bruce F. Cain Memorial Award Lecture Cancer Res. 56, 5533-5546 (Pubitemid 26422147)
59. Willmore, E., Frank, A. J., Padget, K., Tilby, M. J., and Austin, C. A. (1998) Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique Mol. Pharmacol. 54, 78-85 (Pubitemid 28337589)
60. Pfister, T. D., Reinhold, W. C., Agama, K., Gupta, S., Khin, S. A., Kinders, R. J., Parchment, R. E., Tomaszewski, J. E., Doroshow, J. H., and Pommier, Y. (2009) Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity Mol. Cancer Ther.s 8, 1878-1884
61. Pfister, T. D., Hollingshead, M., Kinders, R. J., Zhang, Y., Evrard, Y. A., Ji, J., Khin, S. A., Borgel, S., Stotler, H., Carter, J., Divelbiss, R., Kummar, S., Pommier, Y., Parchment, R., Tomaszewski, J. E., and Doroshow, J. H. Development and validation of a pharmacodynamic immunoassay for topoisomerase I in mouse xenografts for preclinical modeling and clinical trials. PLoS ONE 2012, in press.
62. Murai, J., Huang, S.-y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., and Pommier, Y. (2012) Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors Cancer Res. 72, 5588-5599
63. Makeyev, Y., Muggia, F. M., Rajan, A., Giaccone, G., Furuta, T., and Rougier, P. (2012) in DNA Topoisomerases and Cancer (Pommier, Y., Ed.) Springer, New York.
64. Vo, T. T., Ryan, J., Carrasco, R., Neuberg, D., Rossi, D. J., Stone, R. M., Deangelo, D. J., Frattini, M. G., and Letai, A. (2012) Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML Cell 151, 344-355
65. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Potmesil, M. (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts Science 246, 1046-1048 (Pubitemid 20010531)
66. Brangi, M., Litman, T., Ciotti, M., Nishiyama, K., Kohlhagen, G., Takimoto, C., Robey, R., Pommier, Y., Fojo, T., and Bates, S. E. (1999) Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells Cancer Res. 59, 5938-5946 (Pubitemid 30004955)
67. Teicher, B. A. (2008) Next generation topoisomerase I inhibitors: Rationale and biomarker strategies Biochem. Pharmacol. 75, 1262-1271 (Pubitemid 351305209)
68. Reinhold, W. C., Sunshine, M., Liu, H., Varma, S., Kohn, K. W., Morris, J., Doroshow, J., and Pommier, Y. (2012) CellMiner: A web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set Cancer Res. 72, 3499-3511
69. Kohlhagen, G., Paull, K., Cushman, M., Nagafufuji, P., and Pommier, Y. (1998) Protein-linked DNA strand breaks induced by NSC 314622, a non-camptothecin topoisomerase I poison Mol. Pharmacol. 54, 50-58 (Pubitemid 28337586)
70. Pommier, Y. and Cushman, M. (2009) The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives Mol. Cancer Ther. 8, 1008-1014
71. Tanizawa, A., Fujimori, A., Fujimori, Y., and Pommier, Y. (1994) Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials J. Natl. Cancer Inst. 86, 836-842 (Pubitemid 24164661)
72. Kinders, R., Hollingshead, M. G., Lawrence, S., Ji, J., Tabb, B., Bonner, W. M., Pommier, Y., Rubinstein, L., Evrard, Y. A., Parchment, R. E., Tomaszewski, J. E., and Doroshow, J. H. (2010) Development of a validated immunofluorescence assay for {gamma}H2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity Clin. Cancer Res. 16, 5447-5457
73. Sooryakumar, D., Dexheimer, T. S., Teicher, B. A., and Pommier, Y. (2011) Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor genz-644282 Mol. Cancer Ther. 10, 1490-1499
74. Burden, D. A. and Osheroff, N. (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme Biochim. Biophys. Acta 1400, 139-154 (Pubitemid 28475100)
75. Zwelling, L. A., Michaels, S., Erickson, L. C., Ungerleider, R. S., Nichols, M., and Kohn, K. W. (1981) Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4′-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin Biochemistry 20, 6553-6563 (Pubitemid 12186507)
76. Long, B. H., Musial, S. T., and Brattain, M. G. (1984) Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship Biochemistry 23, 1183-1188 (Pubitemid 14174513)
77. Zechiedrich, E. L., Christiansen, K., Andersen, A. H., Westergaard, O., and Osheroff, N. (1989) Double-stranded DNA cleavage/religation of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate Biochemistry 28, 6229-6236 (Pubitemid 19202012)
78. Doroshow, J. H. (1996) in Cancer Chemotherapy and Biotherapy (Chabner, B. A. and Longo, D. L., Eds.) 2nd ed., Lippincott-Raven, Philadelphia.
79. Mir, O., Dahut, W., Goldwasser, F., and Heery, C. (2012) in DNA Topoisomerases and Cancer (Pommier, Y., Ed.) Springer Humana Press, New York.
80. Tewey, K. M., Chen, G. L., Nelson, E. M., and Liu, L. F. (1984) Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II J. Biol. Chem. 259, 9182-9187 (Pubitemid 14098903)
81. Ross, W. E., Glaubiger, D. L., and Kohn, K. W. (1978) Protein-associated DNA breaks in cells treated with adriamycin or ellipticine Biochim. Biophys. Acta 519, 23-30 (Pubitemid 8371696)
82. Pommier, Y., Schwartz, R. E., Kohn, K. W., and Zwelling, L. A. (1984) Formation and rejoining of deoxyribonucleic acid double-strand breaks induced in isolated cell nuclei by antineoplastic intercalating agents Biochemistry 23, 3194-3201 (Pubitemid 14056884)
83. Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L. S., Lyu, Y. L., Liu, L. F., and Yeh, E. T. (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity Nat. Med. 18, 1639-1642
84. Low, R. L., Orton, S., and Friedman, D. B. (2003) A truncated form of DNA topoisomerase IIbeta associates with the mtDNA genome in mammalian mitochondria Eur. J. Biochem. 270, 4173-4186 (Pubitemid 37281636)
85. Chen, G. L., Yang, L., Rowe, T. C., Halligan, B. D., Tewey, K. M., and Liu, L. F. (1984) Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II J. Biol.l Chem. 259, 13560-13566 (Pubitemid 15221834)
86. Long, B. H., Musial, S. T., and Brattain, M. G. (1985) Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide Cancer Res. 45, 3106-3112 (Pubitemid 15007180)
87. Kerrigan, D., Pommier, Y., and Kohn, K. W. (1987) Protein-linked DNA strand breaks produced by etoposide and teniposide in Mouse L1210 and Human VA-13 and HT-29 cell lines: relationship to cytotoxicity NCI Monogr. 4, 117-121 (Pubitemid 17138186)
88. Pommier, Y., Capranico, G., Orr, A., and Kohn, K. W. (1991) Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs J. Mol. Biol. 222, 909-924 (Pubitemid 121003479)
89. Pommier, Y., Orr, A., Kohn, K. W., and Riou, J. F. (1992) Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c- myc proto-oncogene Cancer Res. 52, 3125-3130
90. Cornarotti, M., Tinelli, S., Willmore, E., Zunino, F., Fisher, L. M., Austin, C. A., and Capranico, G. (1996) Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180) Mol. Pharmacol. 50, 1463-1471 (Pubitemid 26425100)
91. Willmore, E., Errington, F., Tilby, M. J., and Austin, C. A. (2002) Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells Biochem. Pharmacol. 63, 1807-1815 (Pubitemid 34603445)
92. Felix, C. A., Kolaris, C. P., and Osheroff, N. (2006) Topoisomerase II and the etiology of chromosomal translocations DNA Repair (Amsterdam) 5, 1093-1108 (Pubitemid 44291622)
93. Azarova, A. M., Lyu, Y. L., Lin, C. P., Tsai, Y. C., Lau, J. Y., Wang, J. C., and Liu, L. F. (2007) From the Cover: Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies Proc. Natl. Acad. Sci. U.S.A. 104, 11014-11019 (Pubitemid 47175218)
94. Cowell, I. G., Sondka, Z., Smith, K., Lee, K. C., Manville, C. M., Sidorczuk-Lesthuruge, M., Rance, H. A., Padget, K., Jackson, G. H., Adachi, N., and Austin, C. A. (2012) Model for MLL translocations in therapy-related leukemia involving topoisomerase IIbeta-mediated DNA strand breaks and gene proximity Proc. Natl. Acad. Sci. U.S.A. 109, 8989-8994
95. Hawtin, R. E., Stockett, D. E., Byl, J. A., McDowell, R. S., Nguyen, T., Arkin, M. R., Conroy, A., Yang, W., Osheroff, N., and Fox, J. A. (2010) Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II PLoS ONE 5, e10186
96. Gao, H., Huang, K. C., Yamasaki, E. F., Chan, K. K., Chohan, L., and Snapka, R. M. (1999) XK469, a selective topoisomerase IIbeta poison Proc. Natl. Acad. Sci. U.S.A. 96, 12168-12173 (Pubitemid 29502876)
97. Andoh, T. (1998) Bis(2,6-dioxopiperazines), catalytic inhibitors of DNA topoisomerase II, as molecular probes, cardioprotectors and antitumor drugs Biochimie 80, 235-246 (Pubitemid 28206039)
98. Bau, J. T. and Kurz, E. U. (2011) Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha Biochem. Pharmacol. 81, 345-354
99. Maxwell, A. (1999) DNA gyrase as a drug target Biochem. Soc. Trans. 27, 48-53 (Pubitemid 29086006)
100. Drlica, K., Hiasa, H., Kerns, R., Malik, M., Mustaev, A., and Zhao, X. (2009) Quinolones: action and resistance updated Curr. Top. Med. Chem. 9, 981-998
101. Lesher, G. Y., Froelich, E. J., Gruett, M. D., Bailey, J. H., and Brundage, R. P. (1962) 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents J. Med. Pharm. Chem. 91, 1063-1065
102. Gellert, M., Mizuuchi, K., O'Dea, M. H., and Nash, H. A. (1976) DNA gyrase: an enzyme that introduces superhelical turns into DNA Proc. Natl. Acad. Sci. U.S.A. 73, 3872-3876
103. Zhang, Z., Cheng, B., and Tse-Dinh, Y. C. (2011) Crystal structure of a covalent intermediate in DNA cleavage and rejoining by Escherichia coli DNA topoisomerase I Proc. Natl. Acad. Sci. U.S.A. 108, 6939-6944
104. Cheng, B., Shukla, S., Vasunilashorn, S., Mukhopadhyay, S., and Tse-Dinh, Y. C. (2005) Bacterial cell killing mediated by topoisomerase I DNA cleavage activity J. Biol. Chem. 280, 38489-38495 (Pubitemid 43853747)
105. Tse-Dinh, Y. C. (2009) Bacterial topoisomerase I as a target for discovery of antibacterial compounds Nucleic Acids Res. 37, 731-737
106. Perry, K. and Mondragon, A. (2003) Structure of a complex between E. coli DNA topoisomerase I and single-stranded DNA Structure 11, 1349-1358 (Pubitemid 37412417)
107. Changela, A., DiGate, R. J., and Mondragon, A. (2007) Structural studies of E. coli topoisomerase III-DNA complexes reveal a novel type IA topoisomerase-DNA conformational intermediate J. Mol. Biol. 368, 105-118 (Pubitemid 46441213)
108. Haffner, M. C., Aryee, M. J., Toubaji, A., Esopi, D. M., Albadine, R., Gurel, B., Isaacs, W. B., Bova, G. S., Liu, W., Xu, J., Meeker, A. K., Netto, G., De Marzo, A. M., Nelson, W. G., and Yegnasubramanian, S. (2010) Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements Nat. Genet. 42, 668-675
109. Jarvinen, T. A. and Liu, E. T. (2006) Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes - molecular basis for combination chemotherapy in cancer Curr. Cancer Drug Targets 6, 579-602 (Pubitemid 44691001)
110. Al-Kuraya, K., Novotny, H., Bavi, P., Siraj, A. K., Uddin, S., Ezzat, A., Sanea, N. A., Al-Dayel, F., Al-Mana, H., Sheikh, S. S., Mirlacher, M., Tapia, C., Simon, R., Sauter, G., Terracciano, L., and Tornillo, L. (2007) HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer J. Clin. Pathol. 60, 768-772 (Pubitemid 47056905)
111. Ju, B. G., Lunyak, V. V., Perissi, V., Garcia-Bassets, I., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (2006) A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription Science 312, 1798-1802 (Pubitemid 43962898)
112. Kruczynski, A., Vandenberghe, I., Pillon, A., Pesnel, S., Goetsch, L., Barret, J. M., Guminski, Y., Le Pape, A., Imbert, T., Bailly, C., and Guilbaud, N. (2011) Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system Invest. New Drugs 29, 9-21
113. Pesnel, S., Guminski, Y., Pillon, A., Lerondel, S., Imbert, T., Guilbaud, N., Kruczynski, A., Bailly, C., and Le Pape, A. (2011) 99mTc-HYNIC-spermine for imaging polyamine transport system-positive tumours: preclinical evaluation Eur. J. Nucl. Med. Mol. Imaging 38, 1832-1841
114. Hughes, B. (2010) Antibody-drug conjugates for cancer: poised to deliver? Nature reviews Drug Discovery 9, 665-667
115. Dexheimer, T. S., Antony, S., Marchand, C., and Pommier, Y. (2008) Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy Anticancer Agents Med. Chem. 8, 381-389 (Pubitemid 351761423)
116. Huang, S. Y., Pommier, Y., and Marchand, C. (2011) Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors Expert Opin. Ther. Pat. 21, 1285-1292
117. Yang, S.-W., Burgin, A. B., Huizenga, B. N., Robertson, C. A., Yao, K. C., and Nash, H. A. (1996) A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases Proc. Natl. Acad. Sci. U.S.A. 93, 11534-11539 (Pubitemid 26347156)
118. Pouliot, J. J., Yao, K. C., Robertson, C. A., and Nash, H. A. (1999) Yeast gene for a Tyr-DNA phosphodiesterase that repairs topo I covalent complexes Science 286, 552-555
119. Vance, J. R. and Wilson, T. E. (2002) Yeast Tdp1 and Rad1-Rad10 function as redundant pathways for repairing Top1 replicative damage Proc. Natl. Acad. Sci. U.S.A. 99, 13669-13674 (Pubitemid 35215439)
120. Zhang, Y. W., Regairaz, M., Seiler, J. A., Agama, K. K., Doroshow, J. H., and Pommier, Y. (2011) Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells Nucleic Acids Res. 39, 3607-3620
121. Regairaz, M., Zhang, Y.-W., Fu, H., Agama, K. K., Tata, N., Agrawal, S., Aladjem, M. I., and Pommier, Y. (2011) Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I,ÄiÌDNA complexes J. Cell Biol. 195, 739-749
122. Pouliot, J. J., Robertson, C. A., and Nash, H. A. (2001) Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae Genes Cells 6, 677-687 (Pubitemid 32791679)
123. Beidler, D. R. and Cheng, Y. C. (1995) Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity Mol. Pharmacol. 47, 907-914
124. Debethune, L., Kohlhagen, G., Grandas, A., and Pommier, Y. (2002) Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase Nucleic Acids Res. 30, 1198-1204 (Pubitemid 34679693)
125. Zhang, H. F., Tomida, A., Koshimizu, R., Ogiso, Y., Lei, S., and Tsuruo, T. (2004) Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex Cancer Res. 64, 1114-1121 (Pubitemid 38176918)
126. Lin, C. P., Ban, Y., Lyu, Y. L., Desai, S. D., and Liu, L. F. (2008) A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes J. Biol. Chem. 283, 21074-21083
127. Pommier, Y., Barcelo, J. M., Rao, V. A., Sordet, O., Jobson, A. G., Thibaut, L., Miao, Z. H., Seiler, J. A., Zhang, H., Marchand, C., Agama, K., Nitiss, J. L., and Redon, C. (2006) Repair of topoisomerase I-mediated DNA damage Prog. Nucleic Acid Res. Mol. Biol. 81, 179-229 (Pubitemid 44767505)
128. Davies, D. R., Interthal, H., Champoux, J. J., and Hol, W. G. (2002) Insights into substrate binding and catalytic mechanism of human tyrosyl-DNA phosphodiesterase (Tdp1) from vanadate and tungstate-inhibited structures J. Mol. Biol. 324, 917-932 (Pubitemid 41782983)
129. Davies, D. R., Interthal, H., Champoux, J. J., and Hol, W. G. (2002) The crystal structure of human tyrosyl-DNA phosphodiesterase, Tdp1 Structure (Cambridge) 10, 237-248 (Pubitemid 34164601)
130. Davies, D. R., Interthal, H., Champoux, J. J., and Hol, W. G. (2003) Crystal structure of a transition state mimic for tdp1 assembled from vanadate, DNA, and a topoisomerase I-derived Peptide Chem. Biol. 10, 139-147 (Pubitemid 36250972)
131. Cortes Ledesma, F., El Khamisy, S. F., Zuma, M. C., Osborn, K., and Caldecott, K. W. (2009) A human 5′-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage Nature 461, 674-678
132. Virgen-Slane, R., Rozovics, J. M., Fitzgerald, K. D., Ngo, T., Chou, W., van der Heden van Noort, G. J., Filippov, D. V., Gershon, P. D., and Semler, B. L. (2012) An RNA virus hijacks an incognito function of a DNA repair enzyme Proc. Natl. Acad. Sci. U.S.A. 10.1073/pnas.1208096109
133. Jones, S. A., Boregowda, R., Spratt, T. E., and Hu, J. (2012) In vitro epsilon RNA-dependent protein priming activity of human hepatitis B virus polymerase J. Virol. 86, 5134-5150
134. Zhang, J. Q., Wang, J. J., Li, W. J., Huang, L., Tian, L., Xue, J. L., Chen, J. Z., and Jia, W. (2009) Cellular protein TTRAP interacts with HIV-1 integrase to facilitate viral integration Biochem. Biophys. Res. Commun. 387, 256-260
135. Shi, K., Kurahashi, K., Gao, R., Tsutakawa, S. E., Tainer, J. A., Pommier, Y., and Aihara, H. (2012) Structural basis for recognition of 5′-phosphotyrosine adducts by Tdp2 Nat. Struct. Mol. Biol. 19, 1372-1377
136. Schellenberg, M. J., Appel, C. D., Adhikari, S., Robertson, P. D., Ramsden, D. A., and Williams, R. S. (2012) Mechanism of repair of 5′-topoisomerase II-DNA adducts by mammalian tyrosyl-DNA phosphodiesterase 2 Nat. Struct. Mol. Biol. 19, 1363-1371
137. Murai, J., Huang, S. Y., Das, B. B., Dexheimer, T. S., Takeda, S., and Pommier, Y. (2012) Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells J. Biol. Chem. 287, 12848-12857
138. Gao, R., Huang, S. Y., Marchand, C., and Pommier, Y. (2012) Biochemical characterization of human tyrosyl-DNA phosphodiesterase 2 (TDP2/TTRAP): A Mg2+/Mn2+-dependent phosphodiesterase specific for the repair of topoisomerase cleavage complexes J. Biol. Chem. 287, 30842-30852
139. Nitiss, K. C., Malik, M., He, X., White, S. W., and Nitiss, J. L. (2006) Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage Proc. Natl. Acad. Sci. U.S.A. 103, 8953-8958 (Pubitemid 43902515)
140. Zeng, Z., Sharma, A., Ju, L., Murai, J., Umans, L., Vermeire, L., Pommier, Y., Takeda, S., Huylebroeck, D., Caldecott, K. W., and El-Khamisy, S. F. (2012) TDP2 promotes repair of topoisomerase I-mediated DNA damage in the absence of TDP1 Nucleic Acids Res. 40, 8371-8380
141. Takashima, H., Boerkoel, C. F., John, J., Saifi, G. M., Salih, M. A., Armstrong, D., Mao, Y., Quiocho, F. A., Roa, B. B., Nakagawa, M., Stockton, D. W., and Lupski, J. R. (2002) Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy Nat. Genet. 32, 267-272
142. Interthal, H., Chen, H. J., Kehl-Fie, T. E., Zotzmann, J., Leppard, J. B., and Champoux, J. J. (2005) SCAN1 mutant Tdp1 accumulates the enzyme - DNA intermediate and causes camptothecin hypersensitivity EMBO J. 24, 2224-2233 (Pubitemid 40961806)
143. Interthal, H., Pouliot, J. J., and Champoux, J. J. (2001) The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily Proc. Natl. Acad. Sci. U.S.A. 98, 12009-12014 (Pubitemid 32959817)
144. Cusack, J. C., Jr., Liu, R., Houston, M., Abendroth, K., Elliott, P. J., Adams, J., and Baldwin, A. S., Jr. (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition Cancer Res. 61, 3535-3540 (Pubitemid 32694955)
145. Zhang, A., Lyu, Y. L., Lin, C. P., Zhou, N., Azarova, A. M., Wood, L. M., and Liu, L. F. (2006) A protease pathway for the repair of topoisomerase II-DNA covalent complexes J. Biol. Chem. 281, 35997-36003 (Pubitemid 46041332)
146. Lin, C. P., Ban, Y., Lyu, Y. L., and Liu, L. F. (2009) Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double-strand breaks at arrested replication forks J. Biol. Chem. 284, 28084-28092
147. Takeshita, T., Wu, W., Koike, A., Fukuda, M., and Ohta, T. (2009) Perturbation of DNA repair pathways by proteasome inhibitors corresponds to
148. Zwelling, L. A., Kerrigan, D., Pommier, Y., Michaels, S., Steren, A., and Kohn, K. W. (1982) Formation and resealing of intercalator-induced DNA strand breaks in permeabilized L1210 cells without the stimulated synthesis of poly(ADP-ribose) J. Biol. Chem. 257, 8957-8963 (Pubitemid 12004207)
149. Bowman, K. J., Newell, D. R., Calvert, A. H., and Curtin, N. J. (2001) Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro Br. J. Cancer 84, 106-112 (Pubitemid 32102513)
150. Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehar, J., Kryukov, G. V., Sonkin, D., Reddy, A., Liu, M., Murray, L., Berger, M. F., Monahan, J. E., Morais, P., Meltzer, J., Korejwa, A., Jane-Valbuena, J., Mapa, F. A., Thibault, J., Bric-Furlong, E., Raman, P., Shipway, A., Engels, I. H., Cheng, J., Yu, G. K., Yu, J., Aspesi, P., de Silva, M., Jagtap, K., Jones, M. D., Wang, L., Hatton, C., Palescandolo, E., Gupta, S., Mahan, S., Sougnez, C., Onofrio, R. C., Liefeld, T., MacConaill, L., Winckler, W., Reich, M., Li, N., Mesirov, J. P., Gabriel, S. B., Getz, G., Ardlie, K., Chan, V., Myer, V. E., Weber, B. L., Porter, J., Warmuth, M., Finan, P., Harris, J. L., Meyerson, M., Golub, T. R., Morrissey, M. P., Sellers, W. R., Schlegel, R., and Garraway, L. A. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 483, 603-307
151. Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., Liu, Q., Iorio, F., Surdez, D., Chen, L., Milano, R. J., Bignell, G. R., Tam, A. T., Davies, H., Stevenson, J. A., Barthorpe, S., Lutz, S. R., Kogera, F., Lawrence, K., McLaren-Douglas, A., Mitropoulos, X., Mironenko, T., Thi, H., Richardson, L., Zhou, W., Jewitt, F., Zhang, T., O'Brien, P., Boisvert, J. L., Price, S., Hur, W., Yang, W., Deng, X., Butler, A., Choi, H. G., Chang, J. W., Baselga, J., Stamenkovic, I., Engelman, J. A., Sharma, S. V., Delattre, O., Saez-Rodriguez, J., Gray, N. S., Settleman, J., Futreal, P. A., Haber, D. A., Stratton, M. R., Ramaswamy, S., McDermott, U., and Benes, C. H. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells Nature 483, 570-575
152. Martin, S. E., Wu, Z. H., Gehlhaus, K., Jones, T. L., Zhang, Y. W., Guha, R., Miyamoto, S., Pommier, Y., and Caplen, N. J. (2011) RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors Curr. Cancer Drug Targets 11, 976-986
153. Zoppoli, G., Regairaz, M., Leo, E., Reinhold, W. C., Varma, S., Ballestrero, A., Doroshow, J. H., and Pommier, Y. (2012) Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents Proc. Natl. Acad. Sci. U.S.A. 109, 15030-15035
154. Kinders, R. J., Hollingshead, M., Khin, S., Rubinstein, L., Tomaszewski, J. E., and Doroshow, J. H. (2008) Parchment, R. E. Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly(ADP-ribose) polymerase in tumor biopsies of mouse xenografts Clin. Cancer Res. 14, 6877-6885
155. Stewart, L., Redinbo, M. R., Qiu, X., Hol, W. G., and Champoux, J. J. (1998) A model for the mechanism of human topoisomerase I Science 279, 1534-1541 (Pubitemid 28217077)